Details

Autor(en) / Beteiligte

• Piccirillo, Maria Carmela
• Chu, Quincy
• Bradbury, Penelope
• Tu, Wei
• Coschi, Courtney H.
• Grosso, Federica
• Florescu, Marie
• Mencoboni, Manlio
• Goffin, John R.
• Pagano, Maria
• Ciardiello, Fortunato
• Cecere, Fabiana Letizia
• Vincent, Mark
• Ferrara, Roberto
• Dawe, David E.
• Hao, Desiree
• Lee, Christopher W.
• Morabito, Alessandro
• Gridelli, Cesare
• Cavanna, Luigi
• Iqbal, Mussawar
• Blais, Normand
• Leighl, Natasha B.
• Wheatley-Price, Paul
• Tsao, Ming-Sound
• Ugo, Francesca
• El-Osta, Hazem
• Gargiulo, Piera
• Gaudreau, Pierre-Olivier
• Tu, Dongsheng
• Sederias, Joana
• Brown-Walker, Pamela
• Perrone, Francesco
• Seymour, Lesley
• Laurie, Scott A.

Titel

Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)

Ist Teil von

• Journal of thoracic oncology, 2023-06, Vol.18 (6), p.813-819

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2023

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Immune checkpoint inhibitors have activity in mesothelioma. IND.227 was a phase 2 trial (120 patients planned) comparing progression-free survival of standard platinum and pemetrexed (CP) versus CP + pembrolizumab (pembro) versus pembro. Accrual to the pembro arm was discontinued on the basis of interim analysis (IA—16 wk disease control rate). CP + pembro was tolerable, with progression-free survival similar between arms and median survival and overall response rate higher than those of CP alone (19.8 mo [95% confidence interval or CI: 8.4–41.36] versus 8.9 mo [95% CI: 5.3–12.8] and 47% [95% CI: 24%–71%] versus 19% [95% CI: 5%–42%], respectively). The subsequent phase 3 trial has completed accrual; results are expected in 2023.